Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
BMC Cancer|July 28, 2011
Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFYSylvia Haas, Sebastian M Schellong, Ulrich Tebbe, et al.
Journal of Thrombosis and Thrombolysis|June 21, 2006
Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM studyRussell D Hull, Sebastian M Schellong, Victor F Tapson, et al.
Stroke|November 3, 2012
Venous thromboembolism risk in ischemic stroke patients receiving extended-duration enoxaparin prophylaxis: results from the EXCLAIM studyAlexander G G Turpie, Russell D Hull, Sebastian M Schellong, et al.
Archives of Internal Medicine|December 10, 2003
Venous thrombosis after long-haul flightsThomas Schwarz, Gabriele Siegert, Wolfram Oettler, et al.
Annals of Internal Medicine|July 13, 2010
Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trialRussell D Hull, Sebastian M Schellong, Victor F Tapson, et al.
Thrombosis and Haemostasis|October 3, 2013
Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients. Subgroup analysis from the EXCLAIM randomised trialRoger D Yusen, Russell D Hull, Sebastian M Schellong, et al.
VASA. Zeitschrift Fur Gefasskrankheiten|June 2, 2018
Indicators of outcome quality in peripheral arterial disease revascularisations - a Delphi expert consensusHenrik Christian Rieß, Eike Sebastian Debus, Thea Schwaneberg, et al.
The New England Journal of Medicine|September 3, 2013
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism, Harry R Büller, Hervé Décousus, et al.
Thrombosis and Haemostasis|August 2, 2019
Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE RegistrySebastian M Schellong, Samuel Z Goldhaber, Jeffrey I Weitz, et al.
Plos One|October 30, 2016
Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF RegistrySylvia Haas, Hugo Ten Cate, Gabriele Accetta, et al.
Pageof 4